CO5261608A1 - Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina - Google Patents

Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina

Info

Publication number
CO5261608A1
CO5261608A1 CO00094330A CO00094330A CO5261608A1 CO 5261608 A1 CO5261608 A1 CO 5261608A1 CO 00094330 A CO00094330 A CO 00094330A CO 00094330 A CO00094330 A CO 00094330A CO 5261608 A1 CO5261608 A1 CO 5261608A1
Authority
CO
Colombia
Prior art keywords
suspension
oxcarbazepine
composition according
milliliter
grams
Prior art date
Application number
CO00094330A
Other languages
English (en)
Inventor
Sigg Juergen
Michael Billington
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10866648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5261608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5261608A1 publication Critical patent/CO5261608A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina, y que tiene, cuando se agita, una viscosidad en la escala de 5 a 52 mPa. s. Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina y una mezcla de carboximetilcelulosa y celulosa microcristalina, en una escala del 1.25 al 1.95 por ciento (gramos/mililitro)de la composición total. Una composición de acuerdo con la reivindicación 2, en donde la proporción de la carboximetilcelulosa a la celulosa microcristalina en la mezcla es de 1: 5 a 1:12. Una composición de acuerdo con la reivindicación 2 ó 3, en donde la carboximetilcelulosa en la mezcla es una sal sódica. Una composición de acuerdo con cualquiera de las reivindicaciones 1 a 4, la cual comprende un antioxidante. Una composición de acuerdo con la reivindicación 5, en donde el antioxidante es ácido ascórbico. Una composición de acuerdo con la reivindicación 5 ó 6, en donde el antioxidante está presente en una escala del 0.75 al 2 por ciento (gramos/mililitro)de la composición total. Una composición de acuerdo con cualquiera de las reivindicaciones anteriores, que tiene un pH en la escala de 2 a 4.Una composición de acuerdo con cualquiera de las reivindicaciones anteriores, la cual comprende oxcarbazepina en una cantidad del 1 al 20 por ciento (gramos/mililitro). Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina y menos del 0.5 por ciento (gramos/mililitro)de hidroxietilcelulosa. Un recipiente que tiene un volumen de llenado de aproximadamente 50 mililitros a aproximadamente 300 mililitros, el cual comprende una suspensión de oxcarbazepina de acuerdo con cualquiera de las reivindicaciones anteriores, y una jeringa dosificadora adaptada para ajustarse a este recipiente. Una composición farmacéutica en la forma de una suspensión tixotrópica oral que comprende el 6 por ciento (gramos/mililitro)de oxcarbazepina, y que tiene, cuando se agita, una viscosidad en la escala de 5 a 52 mPa. s.
CO00094330A 1999-12-20 2000-12-12 Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina CO5261608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930058.4A GB9930058D0 (en) 1999-12-20 1999-12-20 Organic compounds

Publications (1)

Publication Number Publication Date
CO5261608A1 true CO5261608A1 (es) 2003-03-31

Family

ID=10866648

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00094330A CO5261608A1 (es) 1999-12-20 2000-12-12 Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina

Country Status (34)

Country Link
US (1) US8119148B2 (es)
EP (2) EP1437127A1 (es)
JP (2) JP4588281B2 (es)
KR (2) KR20040098034A (es)
CN (1) CN1216594C (es)
AR (1) AR030175A1 (es)
AT (1) ATE269694T1 (es)
AU (1) AU777619B2 (es)
BE (2) BE1013706A5 (es)
BR (1) BR0016524A (es)
CA (1) CA2390029C (es)
CO (1) CO5261608A1 (es)
CZ (1) CZ302737B6 (es)
DE (1) DE60011809T2 (es)
DK (1) DK1239832T3 (es)
ES (1) ES2223641T3 (es)
FR (1) FR2802423B1 (es)
GB (1) GB9930058D0 (es)
HK (1) HK1050474A1 (es)
HU (1) HU226486B1 (es)
IL (2) IL149498A0 (es)
IT (1) ITMI20002717A1 (es)
MX (1) MXPA02006142A (es)
MY (1) MY126868A (es)
NO (1) NO331990B1 (es)
NZ (1) NZ518755A (es)
PE (1) PE20010933A1 (es)
PL (1) PL201331B1 (es)
PT (1) PT1239832E (es)
RU (1) RU2277912C2 (es)
SK (1) SK287553B6 (es)
TR (2) TR200201459T2 (es)
WO (1) WO2001045671A2 (es)
ZA (1) ZA200204863B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
EP1539098B1 (en) 2002-09-20 2011-08-10 Fmc Corporation Cosmetic composition containing microcrystalline cellulose
RU2369393C2 (ru) 2003-09-03 2009-10-10 Новартис Аг Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (en) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Solid and liquid dosage forms of an antiepileptic agent
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
EP2359830B1 (en) * 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
CA2773249A1 (en) * 2009-09-10 2011-03-17 Bial-Portela & C.A., S.A. Oral suspension formulations of esclicarbazepine acetate
CN104288104A (zh) * 2014-09-24 2015-01-21 万特制药(海南)有限公司 奥卡西平干混悬剂及其制备方法
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN109010322A (zh) * 2018-07-13 2018-12-18 山东达因海洋生物制药股份有限公司 一种包含奥卡西平的口腔分散膜剂及其制备方法
CN115487145B (zh) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 一种奥卡西平口服混悬液及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4004029A (en) * 1974-05-13 1977-01-18 The Upjohn Company Compositions and method for treating epilepsy and convulsions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
RO81639A2 (ro) * 1981-02-27 1983-06-01 Intreprinderea De Medicamente "Biofarm",Ro Procedeu de obtinere a unei pulberi suspendabile oxrale de ampicilina
CH649080A5 (de) 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4427681A (en) 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
JPS60204713A (ja) 1984-03-30 1985-10-16 Zenyaku Kogyo Kk 水性懸濁組成物
US4693901A (en) 1985-12-10 1987-09-15 Cardinal Biological, Ltd. Shelf stable dairylike products
GB8618847D0 (en) 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
IL90245A (en) 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
EP0373103B1 (de) 1988-11-10 1993-03-31 Ciba-Geigy Ag Flüssige orale Formulierung
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9219524D0 (en) * 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
FR2699077B1 (fr) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のci−981製剤およびその製法
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702151B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702149B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
NZ295132A (en) 1994-10-14 1998-06-26 Janssen Pharmaceutica Nv Sabeluzole aqueous suspension having ph from 8 to 10
DE4443966A1 (de) * 1994-12-09 1996-06-13 Basf Ag Thermoplastische Formmassen
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1277663B1 (it) 1995-09-28 1997-11-11 Crinos Industria Farmaco Sospensioni acquose stabili di mesalazina per uso topico
PT101876B (pt) * 1996-05-27 1999-09-30 Portela & Ca Sa Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida
IT1286496B1 (it) 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
US6037380A (en) * 1997-04-11 2000-03-14 Fmc Corporation Ultra-fine microcrystalline cellulose compositions and process
US6146876A (en) * 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HU226486B1 (en) 2009-03-02
MXPA02006142A (es) 2002-12-05
RU2277912C2 (ru) 2006-06-20
CZ20022138A3 (cs) 2002-09-11
US20030004155A1 (en) 2003-01-02
GB9930058D0 (en) 2000-02-09
NO331990B1 (no) 2012-05-21
ITMI20002717A1 (it) 2002-06-15
CN1216594C (zh) 2005-08-31
EP1239832B1 (en) 2004-06-23
PT1239832E (pt) 2004-10-29
US8119148B2 (en) 2012-02-21
IL149498A (en) 2011-05-31
RU2002119210A (ru) 2004-02-27
CZ302737B6 (cs) 2011-10-12
IL149498A0 (en) 2002-11-10
HUP0203782A2 (hu) 2003-03-28
TR200201459T2 (tr) 2002-09-23
CA2390029C (en) 2010-01-26
DK1239832T3 (da) 2004-08-09
BR0016524A (pt) 2002-09-24
BE1014502A5 (fr) 2003-11-04
WO2001045671A3 (en) 2002-02-21
AU777619B2 (en) 2004-10-21
NO20022849D0 (no) 2002-06-14
CA2390029A1 (en) 2001-06-28
AR030175A1 (es) 2003-08-13
MY126868A (en) 2006-10-31
KR100496368B1 (ko) 2005-06-21
EP1239832A2 (en) 2002-09-18
AU2511801A (en) 2001-07-03
HK1050474A1 (en) 2003-06-27
FR2802423B1 (fr) 2005-03-25
ZA200204863B (en) 2003-03-17
DE60011809T2 (de) 2005-06-30
JP4588281B2 (ja) 2010-11-24
DE60011809D1 (en) 2004-07-29
KR20040098034A (ko) 2004-11-18
PL355535A1 (en) 2004-05-04
PL201331B1 (pl) 2009-03-31
JP2006312651A (ja) 2006-11-16
ATE269694T1 (de) 2004-07-15
SK287553B6 (sk) 2011-01-04
TR200402419T4 (tr) 2004-12-21
SK8652002A3 (en) 2002-12-03
NZ518755A (en) 2004-04-30
NO20022849L (no) 2002-06-14
WO2001045671A2 (en) 2001-06-28
ES2223641T3 (es) 2005-03-01
JP2003518036A (ja) 2003-06-03
FR2802423A1 (fr) 2001-06-22
PE20010933A1 (es) 2001-09-17
CN1411367A (zh) 2003-04-16
EP1437127A1 (en) 2004-07-14
HUP0203782A3 (en) 2005-01-28
KR20020062658A (ko) 2002-07-26
BE1013706A5 (fr) 2002-06-04

Similar Documents

Publication Publication Date Title
CO5261608A1 (es) Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina
MXPA03000190A (es) Composicion para el suministro del factor de crecimiento hamtopoyetico.
BR0211736A (pt) Formulação para suspensão oral estabilizada
MXPA05008909A (es) Formulacion intranasal de rotigotina.
MXPA02011543A (es) Preparacion de suspensiones inyectables las cuales tienen capacidad de inyeccion mejorada.
PL366314A1 (en) Pharmaceutical compositions
WO2007130906A3 (en) Malleable implants containing demineralized bone matrix
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
BR9810658A (pt) Composições farmacêuticas contendo hemissulfato de eletriptano e cafeìna.
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
AR067077A1 (es) Preparado solido farmaceutico y metodo de produccion del mismo
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
ES2720954T3 (es) Formulaciones estabilizadas de estatina
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
MY135548A (en) Aqueous preparation containing oligopeptides and etherified cyclodextrin
TW200624119A (en) An oral liquid pharmaceutical composition of leukotriene antagonists
UY27229A1 (es) Composición
BR0007473A (pt) Composições tendo estabilidade melhorada
WO2004022699A3 (en) Liquid stable composition of oxazaphosphorine with mesna
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
ATE211002T1 (de) Dextrinhaltige mischung zur verhinderung von chirurgischen verklebungen
PL366513A1 (en) Thickened aqueous compositions
TW200509990A (en) Pharmaceutical formulations
MXPA05013433A (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato.
TNSN07288A1 (en) Composition containing chitosan for sustained drug release

Legal Events

Date Code Title Description
FC Application refused